<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715858</url>
  </required_header>
  <id_info>
    <org_study_id>R07-63</org_study_id>
    <nct_id>NCT00715858</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Inflammatory Markers in Alzheimer's Disease</brief_title>
  <official_title>A Pilot Study Comparing Inflammatory Biomarkers in Blood and CSF in Patients With Alzheimer's Disease and Age-Matched Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the cerebrospinal fluid (CSF) of patients with
      Alzheimer's disease for biomarkers of inflammation and their response to the antibiotics
      doxycycline and rifampin. The results of this preliminary analysis will be used in defining
      the direction of further research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doxycycline and rifampicin are two antibiotics which may be useful in the treatment of
      Alzheimer's disease (AD). Besides their antimicrobial effects they may also decrease specific
      contributors to AD pathology including: 1. amyloid beta, 2. inflammatory mediators, 3.
      proteolytic enzymes, and 4. metal ions. Evidence indicates an inflammatory response in AD.
      This includes complement activation, elevated C-reactive protein (CRP), elevated
      pro-inflammatory cytokines (including IL-1-beta, IL-6, TNF-α, TGF-β, S100-β), chemokine
      alterations (IL-8, MIP-1-alpha, MIP-1-beta, MCP-1), and microglial activation. In our
      previous study of AD patients treated with combined doxycycline and rifampicin versus
      placebo, we demonstrated that antibiotic treatment significantly delayed progression of
      clinical impairment. Treatment also reduced blood CRP levels suggesting an anti-inflammatory
      role of these antibiotics. In this study we suggest analysis of biomarkers including both pro
      and anti-inflammatory cytokines TNF-alpha, IL-1beta, IL-4, IL-10,the chemokine MCP-1 and
      other inflammatory markers in both the cerebrospinal fluid (CSF) and blood from AD patients
      and age-matched controls.

      AD patients are participants in a 12 month randomized clinical trial of doxycyline and
      rifampin or placebo (DARAD) for treatment of AD. Each patient is asked if they wish to
      contribute a sample of CSF and blood at baseline and at 12 months when treatment is
      completed. About half the patients are consenting to this. Since consent is given to the
      lumbar puncture before the double-blinded DARAD treatment is initiated, we expect the
      distribution of samples collected to be random among the four treatment groups. We will
      compare CSF biomarker levels among the four treatment groups. Ten age-matched healthy
      controls are also being asked to contribute CSF and blood samples for comparison. The
      controls are not participants in the DARAD trial.

      We feel that this is an important pilot study to determine whether there are any differences
      in blood or CSF concentrations of commonly studied cytokines between AD patients and normal
      controls. As such, this study could contribute to the search for a diagnostic biomarker.
      Also, it could provide a solid foundation for future studies aimed at elucidating the effects
      of antibiotics on various biomarkers in the blood and CSF of AD patients. From this, we may
      be able to correlate previous findings that antibiotics delay progression of clinical outcome
      in AD with changes in blood or CSF biomarker levels.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IL-1beta</measure>
    <time_frame>baseline and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>baseline and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MCP-1</measure>
    <time_frame>baseline and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-4</measure>
    <time_frame>baseline and 12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-10</measure>
    <time_frame>baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other inflammatory markers.</measure>
    <time_frame>Baseline and 12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1 AD doxycycline + rifampin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with AD allocated to doxycycline 100 mg bid od and rifampin 300 mg od for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 AD doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 AD rifampin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with AD allocated to rifampin 300 mg od od and placebo matched to doxycycline bid for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 AD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with AD allocated to placebo matched to doxycycline and placebo matched to rifampin for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Age-matched cognitively healthy participants (untreated)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>capsule, 100 mg, b.i.d., 12 months</description>
    <arm_group_label>1 AD doxycycline + rifampin</arm_group_label>
    <arm_group_label>2 AD doxycycline</arm_group_label>
    <other_name>Apo-doxy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampin</intervention_name>
    <description>capsule, 300 mg, od, 12 months</description>
    <arm_group_label>1 AD doxycycline + rifampin</arm_group_label>
    <arm_group_label>3 AD rifampin</arm_group_label>
    <other_name>rifampicin</other_name>
    <other_name>Rofact</other_name>
    <other_name>Rifadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo matched to rifampin; placebo matched to doxycycline</description>
    <arm_group_label>2 AD doxycycline</arm_group_label>
    <arm_group_label>3 AD rifampin</arm_group_label>
    <arm_group_label>4 AD placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Giving informed consent to lumbar puncture

          -  Participation in the DARAD clinical trial which requires the following:

          -  diagnosis of probable Alzheimer's disease

          -  SMMSE 14-26 inclusive

          -  community-dwelling

          -  age 50 or greater

          -  caregiver to monitor study medication and report on ADLs, behaviour, etc.

          -  adequate English literacy to complete neuropsychological testing

          -  generally stable level of health

        Exclusion Criteria:

          -  Contraindication to lumbar puncture

          -  DARAD exclusion criteria as follows:

          -  dementia due to other neurodegenerative diseases

          -  cognitive impairment due to head trauma, etc.

          -  stroke or significant cerebrovascular disease

          -  clinically significant cardiac disease such as recent MI, uncontrolled hypertension

          -  taking other anti-dementia treatments or investigational drugs

          -  allergy to doxycycline or rifampin

          -  significant psychiatric conditions like depression

          -  cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D.William Molloy, MB, MRCPI, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brandon M Kucher, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shucui Jiang, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel P Rathbone, MB, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>D. William Molloy, MB</last_name>
    <phone>905-777-3837</phone>
    <phone_ext>12440</phone_ext>
    <email>wmolloy@stpetes.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Timothy I Standish, MA</last_name>
    <phone>905-777-3837</phone>
    <phone_ext>12442</phone_ext>
    <email>tstandish@stpetes.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St.Peter's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M1W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>D. William Molloy, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.controlled-trials.com/</url>
    <description>DARAD Study clinical trial registration on ISRCTN15039674. Details provided.</description>
  </link>
  <reference>
    <citation>Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, Borrie M, Decoteau E, Davidson W, McDougall A, Gnarpe J, O'DONNell M, Chernesky M. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc. 2004 Mar;52(3):381-7.</citation>
    <PMID>14962152</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>William Molloy</name_title>
    <organization>McMaster University</organization>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>dementia</keyword>
  <keyword>inflammation</keyword>
  <keyword>cytokine</keyword>
  <keyword>biomarker</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <keyword>serum</keyword>
  <keyword>doxycycline</keyword>
  <keyword>rifampin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

